These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1082 related items for PubMed ID: 10411562

  • 1. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I.
    J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
    [Abstract] [Full Text] [Related]

  • 2. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW, Gordon R, Greig G, Gresser M, Guay J, Kargman S, Léger S, Mancini JA, O'Neill G, Ouellet M, Rodger IW, Thérien M, Wang Z, Webb JK, Wong E, Chan CC.
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [Abstract] [Full Text] [Related]

  • 3. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
    Riendeau D, Percival MD, Brideau C, Charleson S, Dubé D, Ethier D, Falgueyret JP, Friesen RW, Gordon R, Greig G, Guay J, Mancini J, Ouellet M, Wong E, Xu L, Boyce S, Visco D, Girard Y, Prasit P, Zamboni R, Rodger IW, Gresser M, Ford-Hutchinson AW, Young RN, Chan CC.
    J Pharmacol Exp Ther; 2001 Feb; 296(2):558-66. PubMed ID: 11160644
    [Abstract] [Full Text] [Related]

  • 4. ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitor.
    Harris RR, Black L, Surapaneni S, Kolasa T, Majest S, Namovic MT, Grayson G, Komater V, Wilcox D, King L, Marsh K, Jarvis MF, Nuss M, Nellans H, Pruesser L, Reinhart GA, Cox B, Jacobson P, Stewart A, Coghlan M, Carter G, Bell RL.
    J Pharmacol Exp Ther; 2004 Dec; 311(3):904-12. PubMed ID: 15277581
    [Abstract] [Full Text] [Related]

  • 5. Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
    Gierse JK, Zhang Y, Hood WF, Walker MC, Trigg JS, Maziasz TJ, Koboldt CM, Muhammad JL, Zweifel BS, Masferrer JL, Isakson PC, Seibert K.
    J Pharmacol Exp Ther; 2005 Mar; 312(3):1206-12. PubMed ID: 15494548
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.
    Riendeau D, Charleson S, Cromlish W, Mancini JA, Wong E, Guay J.
    Can J Physiol Pharmacol; 1997 Sep; 75(9):1088-95. PubMed ID: 9365818
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological profile of FK881(ASP6537), a novel potent and selective cyclooxygenase-1 inhibitor.
    Imanishi J, Morita Y, Yoshimi E, Kuroda K, Masunaga T, Yamagami K, Kuno M, Hamachi E, Aoki S, Takahashi F, Nakamura K, Miyata S, Ohkubo Y, Mutoh S.
    Biochem Pharmacol; 2011 Oct 01; 82(7):746-54. PubMed ID: 21745460
    [Abstract] [Full Text] [Related]

  • 8. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.
    Ehrich EW, Dallob A, De Lepeleire I, Van Hecken A, Riendeau D, Yuan W, Porras A, Wittreich J, Seibold JR, De Schepper P, Mehlisch DR, Gertz BJ.
    Clin Pharmacol Ther; 1999 Mar 01; 65(3):336-47. PubMed ID: 10096266
    [Abstract] [Full Text] [Related]

  • 9. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.
    Song Y, Connor DT, Sercel AD, Sorenson RJ, Doubleday R, Unangst PC, Roth BD, Beylin VG, Gilbertsen RB, Chan K, Schrier DJ, Guglietta A, Bornemeier DA, Dyer RD.
    J Med Chem; 1999 Apr 08; 42(7):1161-9. PubMed ID: 10197960
    [Abstract] [Full Text] [Related]

  • 10. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE, Gottesdiener K, Huntington M, Wong P, Larson P, Wildonger L, Gillen L, Dorval E, Waldman SA.
    J Clin Pharmacol; 2000 Dec 08; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and biological evaluation of a novel class of rofecoxib analogues as dual inhibitors of cyclooxygenases (COXs) and lipoxygenases (LOXs).
    Chen QH, Rao PN, Knaus EE.
    Bioorg Med Chem; 2006 Dec 01; 14(23):7898-909. PubMed ID: 16904331
    [Abstract] [Full Text] [Related]

  • 12. 2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors.
    Black WC, Brideau C, Chan CC, Charleson S, Chauret N, Claveau D, Ethier D, Gordon R, Greig G, Guay J, Hughes G, Jolicoeur P, Leblanc Y, Nicoll-Griffith D, Ouimet N, Riendeau D, Visco D, Wang Z, Xu L, Prasit P.
    J Med Chem; 1999 Apr 08; 42(7):1274-81. PubMed ID: 10197970
    [Abstract] [Full Text] [Related]

  • 13. COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro.
    Mohseni H, Zaslau S, McFadden D, Riggs DR, Jackson BJ, Kandzari S.
    J Surg Res; 2004 Jun 15; 119(2):138-42. PubMed ID: 15145695
    [Abstract] [Full Text] [Related]

  • 14. In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.
    Shin SS, Byun Y, Lim KM, Choi JK, Lee KW, Moh JH, Kim JK, Jeong YS, Kim JY, Choi YH, Koh HJ, Park YH, Oh YI, Noh MS, Chung S.
    J Med Chem; 2004 Feb 12; 47(4):792-804. PubMed ID: 14761182
    [Abstract] [Full Text] [Related]

  • 15. The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor.
    Li L, Ji H, Sheng L, Zhang Y, Lai Y, Chen X.
    Eur J Pharmacol; 2009 Apr 01; 607(1-3):244-50. PubMed ID: 19243697
    [Abstract] [Full Text] [Related]

  • 16. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.
    Song Y, Connor DT, Doubleday R, Sorenson RJ, Sercel AD, Unangst PC, Roth BD, Gilbertsen RB, Chan K, Schrier DJ, Guglietta A, Bornemeier DA, Dyer RD.
    J Med Chem; 1999 Apr 08; 42(7):1151-60. PubMed ID: 10197959
    [Abstract] [Full Text] [Related]

  • 17. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach.
    Chan CC, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, Hill RG, Li CS, Mancini J, Penneton M.
    J Pharmacol Exp Ther; 1995 Sep 08; 274(3):1531-7. PubMed ID: 7562530
    [Abstract] [Full Text] [Related]

  • 18. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.
    Argentieri DC, Ritchie DM, Ferro MP, Kirchner T, Wachter MP, Anderson DW, Rosenthale ME, Capetola RJ.
    J Pharmacol Exp Ther; 1994 Dec 08; 271(3):1399-408. PubMed ID: 7996452
    [Abstract] [Full Text] [Related]

  • 19. Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis.
    Kato S, Ogawa Y, Kanatsu K, Okayama M, Watanabe T, Arakawa T, Takeuchi K.
    J Pharmacol Exp Ther; 2002 Nov 08; 303(2):503-9. PubMed ID: 12388629
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological characterization of a selective COX-2 inhibitor MF-tricyclic, [3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone], in multiple preclinical species.
    Rowland SE, Clark P, Gordon R, Mullen AK, Guay J, Dufresne L, Brideau C, Cote B, Ducharme Y, Mancini J, Chan CC, Audoly L, Xu D.
    Eur J Pharmacol; 2007 Apr 10; 560(2-3):216-24. PubMed ID: 17316604
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.